Member Info for David1951c

Some buys are showing as sells. Made two 250k buys at .656 but shown as sells on LSE.

Given Kefi's footprint in RSA and Ethiopia, knowledge and connections, could this become a take over target by one of the major miners to give them a much quickerentry?

Taking the Q1 and Q2 figures suggests revenue in first half could be about $90m which is a 30% increase. Find out in September when interims come out.

Company excited but there is still important milestones to achieve especially MTUP as a step to unlock the next payment by JV partner. I am excited at the potential but until the permits are in place the next phases and timelines are still a way off.

BMV must wonder what's going on - good news and a SP drop of 8% (currently). The market has fundamentally changed in last few years and patience is thin. Good news but not much to go on in terms of firm production with no details about what is needed for MTUPs.

Also at one time there were SK grants available to put towards physical mining activities. Still available?

Been invested here a few years but will not put any more in until the finances are sound. These deals are promising but the company is losing money and another fund raise is more than likely. China deal is worth only about £600k pa. It is a pity that truly transformational news i.e. much bigger deals in revenue terms, is still awaited.

Good news and another important step to production in SK. I have been invested here for more than 5 years and what I find so frustrating is the failure to get the permits and other local requirements completed. MTUP requirements must have been known about but even now it is unclear what is needed and when these will be applied for and gained (hopefully).

Having the local JV partners doing this should enable the process to be quicker and avoid cultural issues etc. but why are these not ready to go? Early work mentioned gives some confidence but production start is dependent on MTUPs which are unclear in timing.

Decided to sell up at a small loss. PRTC don't care a jot about small PIs and next step will probably be to delist or move listing to NY.

In RNS in May KOD said that shipments would take place in June. Is there any update on this or possible delay?

Last year's fund raise was a disaster for shareholders as it was so heavily discounted due to the parlous financial position, which also meant that customers were so concerned and orders dried up. The difference now is that majors are prepared to place repeat orders and there is a pipeline of potential new customers, which suggests more confidence that the company can survive. Latest figures are good but not sufficient to end the possibility of another placement. RNSs and messages don't give complete confidence that another equity raise won't be necessary. When that happens the SP should jump.

The overriding factor is the pitiful market cap and if the financial concerns can be put to bed then this has huge re-rate potential. Of course the range and quality of the customers suggests that funding might be possible without major dilution and I still hope there are alternatives such as an advance from the likes of Unilever or AZ.

I have a large holding for me and live in hope especially with regular updates of good news.

There is a lot of speculation on funding requirements and possible placing in spite of numerous new contracts won in the last six months.

It is difficult to assess the revenue and cash balances and project into the future to determine break-even point in time but clearly Apta are doing business with some household names including Unilever and an unnamed top five biopharma who must be satisfied.

If these two companies each gave an advance of £1.5m (or more) against future work and supply of aptamers then this would see the company through to mid 2025 at least and dispel all the negativity. Apta Board and management must be very frustrated by the time and effort dealing with funding rather than on sales and new contracts.

Useful for those who did not attend IM session this morning. Not enough in the way of hard information and timelines but meetings in SK next week so possibly news on Kochang JV soon.

One amusing part of the session was using a calculator to work out that 40k ounces @ $2,300 = $92m per annum for BMV!

Main risk is not getting all the licences and approvals needed although the involvement of local partners should lessen that risk. Getting into modest production in Korea should not require huge capex as it should be possible from what has already been mined and re-work of tailings using better methods. This would fund mine workings and further exploration.

All quite positive and I am glad I kept investments made more than five years ago. News on Kochang should come in weeks and the impetus from local partners will make the remaining issues less challenging. Reduction in corporate costs from farming out should mean less cash burn and no fund raise until Korea is in production and can finance Batangas.

Anyway I am optimistic but just an amateur investor.

Undoubted potential but not without risks. Just bought two more lots 250k and 200k at 1.8 shown as sells on LSE.

With 10%+ yield PHNX offers a great return and I am satisfied with that. It is hard to understand why the share price remains relatively low and why there is not more buying. The largest shareholders are Japanese and Aberdeen with few above 3%. Possibly this is down to lack of equity investment by institutions and pension funds (ironically) as you might expect them to interested. Their risk assessment and low risk appetite probably means constrained holdings and possibly concern at the sustainability of dividends.

The current dividend cost for 2023 was £520m and the question is whether this is sustainable. It should be through to 2026 based on increased operation cash generation with expenses savings of £250m targeted. More will be revealed when half year report is released in August.

The stand out factor for me is the quality and size of the companies entering into relationships with Apta on a wide range of possible developments. Any one of these could lead to significant revenue which in context is not a lot of money. If expenses are running at £300k per month or £3.6m per annum that could be reached within 12 months IF progress is achieved.

Anyway bought another 500k shares shown on LSE as a sell.

AIM is rubbish right now and for a small cap to raise £6m is a notable achievement. It suggests a lot of people believe that GDR can succeed. Mcap is only around £2.5m and the potential is huge. Risks are there too but there are multiple developments in play so lot to look forward to. GDR need to keep news flowing and roll on decision day in July.

For 12 months ended 30 November should be out this week. Next financial statements should give revenue actually achieved and hopefully a good indication of the current FY. Without more information, buying shares will be a gamble.

Products are very good in their fields but economic situation is a material drag on sales.

It is the quality and size of the biopharma companies plus Unilever that stands out. These companies are wanting to work with a minnow because Aptamer have something that has value and potential. They will do due diligence and be satisfied.

It is hard to estimate the cash and funding position and whilst a fund raise cannot be ruled out, each new deal lessens the risk and the size of any raise. Posters like Porky may not be wrong but the company continue to develop a pipeline with impressive customers any of which could successfully lead to bigger orders and revenue.

It is the range of possible applications that mean Aptamer have a pivotal role and great potential for others developing important offerings. I certainly feel more confident than three months ago.

Having sold last year I keep an eye and news is promising. As with a large number of developing companies on AIM the SP has been crushed and the issue of funding through to and beyond break even is critical. The £2m order recently is great but the financials for the last full financial year are still not out and no detailed trading level updates have been issued. Based on the last financials and interims on their website it is difficult to predict numbers and whether a further fund raise will be required to get to get to positive trading.

There is no information on margins and the loss in the previous 18 months to May 2023 is significant due to expenses. YE results should be announced soon and hopefully will give a clear idea on current performance and allow projection for 2current FY.

More excellent news. It would help to know over what period(s) £465k will be earned and booked. A few more new partnerships like this will really help investors not to fear another discounted equity fund raise, which is still holding the SP back after events of 2023.